From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugsRebecca L. McIntyre(Amsterdam University Medical Centers), Georges E. Janssens(Amsterdam University Medical Centers)EMBO Molecular MedicineAugust 1, 201910.15252/emmm.201809854Cited by 118SaveCiteExport RISWatch citationsRelated PapersPeripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models|Nature Communications|2023|39HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice|iScience|2023|12Plasma triacylglycerol length and saturation level mark healthy aging groups in humans|GeroScience|2024|2